Aptinyx, Inc.’s future is looking increasingly uncertain after it experienced yet another clinical trial failure. Its hopes in the neuropsychiatry space have died following a Phase II flop in Parkinson’s disease (PD) and dementia, prompting the firm to wind down clinical activities for a separate post-traumatic stress disorder (PTSD) asset and focus on cutting costs amid a dwindling cash runway.
The Phase II trial set a 30mg dose of co-lead candidate NYX-458 against placebo for 12 weeks in 99 people with mild cognitive impairment (MCI) or mild dementia due to PD or dementia with Lewy bodies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?